Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mobile team vs. lab: which HPV screening strategy works best for women with HIV?

NCT ID NCT07181278

Knowledge-focused Sponsor: Institut de Recherche pour le Developpement Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two ways to screen for cervical cancer in women with HIV in Cameroon. One way sends self-collected samples to a central lab; the other uses a mobile team that tests and treats on the spot. Researchers want to see which approach helps more women complete all screening steps. About 1,180 women aged 25 to 49 will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a mobile team offering same-day HPV testing and treatment is more effective than sending samples to a central lab, helping more women complete screening.
What could go wrong
This is an observational study comparing two existing strategies, not testing a new treatment. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 49 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women * HIV infection * Age between 25 and 49 years old * Receiving or starting ARV treatment * Agreeing to participate in the study and having signed the consent Exclusion Criteria: * Current pregnancy * Hysterectomy * Treatment of cervical lesions within 12 months * Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.); * Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Deferred inclusion if * menstrual bleeding * Postpartum (\<12 weeks after delivery) * Clinical signs of cervical or pelvic infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer screening HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bafoussam Baptist Hospital

    RECRUITING

    Bafoussam, Cameroon

  • Bandjoun District Hospital

    RECRUITING

    Bandjoun, Cameroon

  • Bingo Hospital

    RECRUITING

    Bafoussam, Cameroon

  • Centre Médical Spécialisé ACHA

    RECRUITING

    Bafoussam, Cameroon

  • Foumbot District Hospital

    RECRUITING

    Foumbot, Cameroon

  • Hôpital Régional Annexe

    RECRUITING

    Bafoussam, Cameroon

More trials for these conditions

Other studies related to the condition(s) this trial covers.